LabCorp and Envigo Complete Innovative Transactions

Expands Covance Capabilities, Creates Independent Research Models and Service Provider

June 3, 2019 - We are excited to inform you that LabCorp and Envigo have completed the previously announced transactions that will strengthen and enhance the way our respective businesses support research in the biopharmaceutical and life sciences industries. LabCorp’s Covance Drug Development segment has completed the acquisition of Envigo’s nonclinical contract research services business, expanding Covance’s global nonclinical drug development capabilities with additional locations and resources. This exciting combination creates a nonclinical contract research organization with significant global scale and expansive capabilities.

What does this mean for our clients?

We will continue to put our clients at the center of everything we do.

This unique and innovative transaction enhances the reach and scope of Covance’s contract research offerings and provides our clients with:

  • Access to an infusion of additional scientific expertise, technical expertise and insights

  • Enhanced nonclinical capabilities including respiratory expertise

  • New and enhanced chemical and crop protection services

  • Access to additional facilities in Europe and the U.S.

  • Access to a full-range of high-quality research models and services through our strategic multi-year collaboration with the new Envigo research models and services business

Our clients can be assured that our expanded organization will remain focused on delivering quality and continuity of their future studies.